Bispecific Antibody Outperforms PD-1 Inhibitor in Advanced Lung Cancer
A New Standard of Care?
CHICAGO — A new bispecific antibody, ivonescimab, combined with chemotherapy showed superior results in treating advanced non-small cell lung cancer (NSCLC) at the ASCO conference. The HARMONi-6 trial results were presented on May 31. The study involved an all-Asian population.
Ivonescimab targets both PD-1 and VEGF, making it a first-in-class treatment. The antibody works by inhibiting two key pathways that cancer cells use to grow and evade the immune system. By targeting both pathways simultaneously, ivonescimab may offer a more effective treatment option for patients with advanced NSCLC.
Will Diversity be a Concern?
The HARMONi-6 trial demonstrated a 34% reduction in the risk of death when ivonescimab was combined with chemotherapy, compared to a PD-1 inhibitor plus chemotherapy. An expert noted that while the results are promising, the all-Asian population of the trial may limit its generalizability to other populations. The trial's findings suggest that ivonescimab may offer a new treatment option for patients with advanced NSCLC.
The lack of diversity in the trial population raises questions about the applicability of the results to other ethnic groups. Despite this limitation, the trial's results are significant, and further studies are needed to confirm the findings in more diverse populations.
Frequently Asked Questions
The success of ivonescimab could lead to a shift in the treatment paradigm for advanced NSCLC, with bispecific antibodies potentially becoming a new standard of care. As research continues, it is likely that we will see further developments in this area.
What is ivonescimab? Ivonescimab is a bispecific antibody that targets both PD-1 and VEGF, making it a first-in-class treatment for advanced NSCLC. How does ivonescimab work? It inhibits two key pathways that cancer cells use to grow and evade the immune system. What were the results of the HARMONi-6 trial? The trial showed a 34% reduction in the risk of death when ivonescimab was combined with chemotherapy.